Welcome to our dedicated page for Takeda Pharm news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharm stock.
The TAK news page on Stock Titan aggregates company-specific coverage for Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE: TAK). Takeda’s own disclosures describe it as a values-based, R&D-driven biopharmaceutical company headquartered in Japan, with core therapeutic and business areas in gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Because of this broad focus and active pipeline, Takeda generates frequent news across clinical, regulatory, partnership and financial topics.
Recent press releases highlight late-stage clinical data and regulatory plans for several key programs. In neuroscience, Takeda has presented Phase 3 results for oveporexton (TAK-861), an investigational oral orexin receptor 2 agonist for narcolepsy type 1, showing statistically significant improvements in excessive daytime sleepiness, cataplexy and quality-of-life measures versus placebo. In immunology and dermatology, the company has reported pivotal Phase 3 data for zasocitinib (TAK-279), an investigational highly selective oral TYK2 inhibitor in moderate-to-severe plaque psoriasis, with studies meeting all primary and ranked secondary endpoints.
Takeda news also covers hematology and rare disease developments. Together with Protagonist Therapeutics, the company has released Phase 3 VERIFY and long-term THRIVE data for rusfertide, an investigational hepcidin mimetic for polycythemia vera, demonstrating durable hematocrit control, reduced phlebotomy requirements and maintained patient-reported outcome improvements. In nephrology, Takeda has shared Phase 1b data for mezagitamab (TAK-079) in primary IgA nephropathy, showing stable kidney function and sustained reductions in proteinuria and Gd-IgA1 levels up to 18 months after the last dose.
In vaccines, Takeda has announced seven-year Phase 3 TIDES trial data for its dengue vaccine QDENGA (TAK-003), reinforcing sustained protection against virologically confirmed dengue and dengue-related hospitalizations and supporting a two-dose regimen. Corporate and pipeline news includes strategic oncology collaborations, such as the global partnership with Innovent Biologics for late-stage assets IBI363 and IBI343, and financial updates on revenue trends, generic erosion impacts and revised full-year forecasts.
Investors and followers of TAK can use this news feed to track Takeda’s clinical milestones, regulatory filings, strategic alliances, portfolio prioritization decisions and IFRS-based financial disclosures as they are reported in press releases and SEC Form 6-K submissions.
Takeda (NYSE:TAK) has received FDA approval for expanded indications of VONVENDI®, their recombinant von Willebrand factor therapy. The expansion includes routine prophylaxis for adults with Type 1 and 2 von Willebrand Disease (VWD) and on-demand and perioperative bleeding management in pediatric VWD patients.
VONVENDI is now the only recombinant VWF replacement therapy approved for both adults and children with VWD, which affects over 3 million people in the U.S. The drug demonstrates a notable half-life of 22.6 hours in adults and 14.3 hours in children, with clinical trials showing that the majority of non-surgical bleeds were treated with just one infusion.
The approval is supported by data from three clinical trials and real-world evidence, marking a significant advancement in VWD treatment standards.
Takeda (NYSE:TAK) reported Q1 FY2025 results showing revenue decline of 3.7% at constant exchange rate (CER) and 8.4% at actual exchange rates (AER), primarily due to VYVANSE® generic erosion. Core operating profit declined 11.9% at CER, while reported operating profit increased 11.0% at AER.
The company achieved significant pipeline milestones, including positive Phase 3 results for oveporexton in narcolepsy type 1, meeting all primary and secondary endpoints. Additionally, Takeda received FDA approval for GAMMAGARD® LIQUID ERC and EC approval for ADCETRIS® in new indications. Despite Q1 impacts, the company maintains its full-year FY2025 outlook announced in May.
Takeda (NYSE:TAK) has received FDA 510(k) clearance for its HyHub™ and HyHub™ Duo devices, designed to simplify the administration of HYQVIA®, an immunoglobulin therapy. These innovative devices reduce the preparation steps by up to 50% for HYQVIA infusions and enable needle-free transfer from vials in home or clinical settings.
The devices, developed with patient and caregiver input, are specifically designed for patients 17 years and older using HYQVIA, which treats primary immunodeficiency (PI) and chronic inflammatory demyelinating polyneuropathy (CIDP). Takeda plans to make these devices available in the U.S. during the second half of fiscal year 2025 at no additional cost to patients. The company has also submitted a CE Mark application for European approval.
Takeda (NYSE:TAK) announced breakthrough results from two Phase 3 studies of oveporexton (TAK-861) for narcolepsy type 1 (NT1) treatment. The FirstLight and RadiantLight trials demonstrated statistically significant improvements across all primary and secondary endpoints with p-values <0.001 at all doses.
The studies showed clinically meaningful improvements in wakefulness, excessive daytime sleepiness, cataplexy, attention, and quality of life, with most participants reaching near-normal ranges. Oveporexton was generally well-tolerated, with no serious treatment-related adverse events reported. Common side effects included insomnia and urinary issues.
Takeda plans to submit regulatory applications globally in fiscal year 2025, aiming to bring this first-in-class oral orexin receptor 2 agonist to market as quickly as possible.
Takeda (NYSE:TAK) has received FDA approval for GAMMAGARD LIQUID ERC, a groundbreaking immunoglobulin therapy for primary immunodeficiency patients aged two and older. This therapy stands out as the only ready-to-use liquid immunoglobulin treatment with low IgA content (≤2 µg/mL in a 10% solution).
The company plans to begin U.S. commercialization in 2026, followed by European Union launch in 2027 under the brand name DEQSIGA®. The product offers dual administration flexibility, being suitable for both intravenous and subcutaneous use, eliminating the need for reconstitution.
In a significant portfolio shift, Takeda announced the planned discontinuation of GAMMAGARD S/D, their first-generation low IgA product, by December 2027. The company will maintain inventory until depletion or expiration, citing manufacturing process limitations in meeting future patient needs.
[ "First and only ready-to-use liquid immunoglobulin therapy with low IgA content approved by FDA", "Dual administration flexibility (intravenous or subcutaneous use)", "Eliminates need for reconstitution, reducing administration burden", "Uses state-of-the-art manufacturing process", "Maintains lowest IgA content among ready-to-use liquid immunoglobulin therapies" ]Summary not available.
The drug achieved its primary endpoint with substantial increases in mean sleep latency, reaching levels similar to healthy individuals. Secondary endpoints showed significant reductions in excessive daytime sleepiness and weekly cataplexy rates. Quality of life measures also showed marked improvements across multiple symptom domains.
The treatment was generally well-tolerated, with most common side effects being insomnia (43%), increased urinary urgency (30%), and frequency (29%). Notably, 95% of participants continued into the long-term extension study. Takeda expects Phase 3 trial results in 2025, positioning oveporexton as a potential first-in-class therapeutic option for NT1.